What is the optimal initial management of the older MCL patient?

被引：8

作者：

Kluin-Nelemans, Johanna C. ^{[1
]}

Doorduijn, Jeanette K. ^{[2
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Haematol, Hanzepl 1, NL-9700 RB Groningen, Netherlands

[2] Erasmus MC Canc Inst, Dept Haematol, S Gravendijkwal 230, NL-3015 CE Rotterdam, Netherlands

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2018年 / 31卷 / 01期

关键词：

Mantle cell lymphoma; Elderly patients; Induction therapy; Maintenance therapy; R-CHOP; Bendamustine; Cytarabine; Lenalidomide; Bortezomib; Toxicity; MANTLE-CELL LYMPHOMA; PROSPECTIVE RANDOMIZED-TRIAL; SINGLE-AGENT LENALIDOMIDE; PROGRESSION-FREE SURVIVAL; NON-HODGKINS-LYMPHOMA; ELDERLY-PATIENTS; PHASE-II; PLUS RITUXIMAB; 1ST-LINE TREATMENT; INDUCTION THERAPY;

D O I：

10.1016/j.beha.2017.07.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The current first line treatment of a patient with mantle cell lymphoma (MCL) is often considered as too toxic for elderly patients. The elderly, however, comprise the majority of the patients with MCL. The results of several recent studies have shown that the outcome of this patient group is not as dismal as in the past. Indeed, if patients are not considered frail, and can tolerate rituximab and moderate intensive chemotherapy such as R-CHOP followed by rituximab maintenance or R-bendamustine, a 4-year overall survival of >80% can be achieved. In this chapter the developments of the regimens, resulting in the standard treatment options for these patients, are discussed. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：99 / 104

页数：6

共 47 条

[1] Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study [J].

Abrahamsson, Anna ;

Albertsson-Lindblad, Alexandra ;

Brown, Peter N. ;

Baumgartner-Wennerholm, Stefanie ;

Pedersen, Lars M. ;

D'Amore, Francesco ;

Nilsson-Ehle, Herman ;

Jensen, Paw ;

Pedersen, Michael ;

Geisler, Christian H. ;

Jerkeman, Mats .

BLOOD, 2014, 124 (08) :1288-1295

[2] Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma [J].

Bauwens, D ;

Maerevoet, M ;

Michaux, L ;

Théate, I ;

Hagemeijer, A ;

Stul, M ;

Danse, E ;

Costantini, S ;

Vannuffel, P ;

Straetmans, N ;

Vekemans, MC ;

Deneys, V ;

Ferrant, A ;

Van Den Neste, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (03) :338-340

[3] Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes [J].

Cheah, C. Y. ;

Chihara, D. ;

Romaguera, J. E. ;

Fowler, N. H. ;

Seymour, J. F. ;

Hagemeister, F. B. ;

Champlin, R. E. ;

Wang, M. L. .

ANNALS OF ONCOLOGY, 2015, 26 (06) :1175-1179

[4] Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma [J].

Cohen, BJ ;

Moskowitz, C ;

Straus, D ;

Noy, A ;

Hedrick, E ;

Zelenetz, A .

LEUKEMIA & LYMPHOMA, 2001, 42 (05) :1015-+

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Management of mantle cell lymphoma in the elderly patient [J].

Doorduijn, Jeanette K. ;

Kluin-Nelemans, Hanneke C. .

CLINICAL INTERVENTIONS IN AGING, 2013, 8 :1229-1236

[7] Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network [J].

Dreyling, M ;

Lenz, G ;

Hoster, E ;

Van Hoof, A ;

Gisselbrecht, C ;

Schmits, R ;

Metzner, B ;

Truemper, L ;

Reiser, M ;

Steinhauer, H ;

Boiron, JM ;

Boogaerts, MA ;

Aldaoud, A ;

Silingardi, V ;

Kluin-Nelemans, HC ;

Hasford, J ;

Parwaresch, R ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2005, 105 (07) :2677-2684

[8] Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Dreyling, M. ;

Geisler, C. ;

Hermine, O. ;

Kluin-Nelemans, H. C. ;

Le Gouill, S. ;

Rule, S. ;

Shpilberg, O. ;

Walewski, J. ;

Ladetto, M. .

ANNALS OF ONCOLOGY, 2014, 25 :83-92

[9]

Dreyling M, 2015, LEUKEMIA LYMPHOMA, P1

[10]

Dreyling Martin, 2009, Hematology Am Soc Hematol Educ Program, P542, DOI 10.1182/asheducation-2009.1.542

← 1 2 3 4 5 →